10-Q: Iterum Therapeutics Q2: ORLYNVAH Launch Amid Funding Doubt

Iterum Therapeutics reports continued net losses and substantial doubt about its ability to continue as a going concern, while preparing for the commercial launch of ORLYNVAH by end of August 2025.

Summary

• Net loss for the three months ended June 30, 2025, was $6.509 million, compared to $4.997 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $11.400 million, a decrease from $12.098 million for the same period in 2024.
• Accumulated deficit reached $497.472 million as of June 30, 2025.
• Cash and cash equivalents stood at $13.026 million as of June 30, 2025.
• Management has identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern for the next 12 months, as existing cash is not believed to be sufficient.
• The company is preparing for the commercial launch of ORLYNVAH in the U.S. by the end of August 2025, in collaboration with EVERSANA Life Science Services, LLC.
• A strategic process to sell, license, or otherwise dispose of sulopenem rights did not result in a transaction acceptable to the board of directors.
• Research and development expenses decreased to $1.591 million for the six months ended June 30, 2025, from $6.052 million in the prior year, primarily due to lower clinical trial and CMC-related costs.
• General and administrative expenses increased to $6.961 million for the six months ended June 30, 2025, from $4.087 million in the prior year, mainly due to increased professional and consulting fees for pre-commercialization activities.
• The Pfizer Promissory Note for $20.0 million, due upon FDA approval of ORLYNVAH, was deferred for an additional three years until October 25, 2029, with the annual interest rate increasing from 8% to 10% starting October 26, 2026.
• Subsequent to June 30, 2025, through August 1, 2025, the company sold 2,525,578 ordinary shares under its 'at the market' (ATM) offering agreement for net proceeds of $2.175 million.

Sentiment

Score: 3

Explanation: While the FDA approval of ORLYNVAH and the initiation of commercialization plans are positive steps, the company's severe liquidity issues, explicit 'going concern' warning, and failure to secure a strategic transaction for its core asset indicate a highly precarious financial position. The need for substantial future capital raises and the inherent risks of commercializing a new drug with limited resources significantly outweigh the positive developments, leading to a negative outlook.

Positives

• Received FDA approval for ORLYNVAH (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women on October 25, 2024.
• Entered into a Product Commercialization Agreement with EVERSANA Life Science Services, LLC in June 2025 for the commercialization of ORLYNVAH in the United States.
• Signed a Commercial Manufacturing and Supply Agreement with ACS Dobfar S.p.A. in July 2025 for the manufacture and supply of ORLYNVAH materials.
• Successfully extended the deferral period for the $20.0 million Pfizer Promissory Note by an additional three years, pushing the maturity date to October 25, 2029.
• Reported a lower net loss for the six months ended June 30, 2025 ($11.4 million) compared to the same period in 2024 ($12.1 million).
• Significantly reduced research and development expenses by $4.461 million for the six months ended June 30, 2025, compared to the prior year.

Negatives

• Identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern, as existing cash and cash equivalents are not believed to fund operations for the next 12 months.
• Incurred net losses in each year since inception, with an accumulated deficit of $497.472 million as of June 30, 2025.
• A strategic process to sell, license, or otherwise dispose of sulopenem rights did not result in any transaction acceptable to the board of directors, necessitating self-commercialization efforts.
• General and administrative expenses increased significantly by $2.874 million for the six months ended June 30, 2025, primarily due to pre-commercialization activities.
• The interest rate on the Pfizer Promissory Note will increase from 8% to 10% annually starting October 26, 2026.
• The company has a limited operating history and no prior experience successfully commercializing pharmaceutical products.
• The volatility of the company's shares and shareholder base, comprised of a large number of retail investors, may hinder or prevent beneficial corporate initiatives due to difficulties in securing sufficient shareholder votes.

Risks

• Identified conditions and events raise substantial doubt about the company's ability to continue as a going concern; failure to obtain additional funding could force delay, reduction, or elimination of development programs or commercialization efforts.
• Incurred net losses in each year since inception and anticipate continued significant losses unless the sulopenem program is successfully commercialized.
• Requires additional capital to fund operations and support the commercial launch of ORLYNVAH and ongoing clinical development; failure to obtain financing when needed or on acceptable terms could be forced to delay, reduce or eliminate product development programs or commercialization efforts.
• Changes in and uncertainty surrounding trade policy, including tariff and customs regulations, or failure to comply with such regulations may have an adverse effect on the business, financial condition and results of operations.
• In the event of inability to raise sufficient capital, the board of directors may determine that liquidation and dissolution of the business is the best method to maximize shareholder value.
• Heavy dependence on the success of the sulopenem program, including the ability to successfully commercialize ORLYNVAH and obtain additional marketing approvals for oral and IV sulopenem.
• Failure to successfully commercialize ORLYNVAH, inability to enter a satisfactory business development transaction, or inability to obtain marketing approval for any other product candidates, or significant delays in doing so, will materially harm the business.
• Serious adverse events or undesirable side effects or other unexpected properties of ORLYNVAH, sulopenem or any other product candidate may be identified during development or after approval that could delay, prevent or cause the withdrawal of regulatory approval, limit commercial potential, or result in significant negative consequences.
• Even though ORLYNVAH has obtained regulatory approval, it may never achieve the market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community that is necessary for commercial success, and the market opportunity may be smaller than estimated.
• Currently has a limited commercial organization; inability to establish and maintain sales, marketing and distribution capabilities with EVERSANA or other third parties, or enter into a strategic alternative, could prevent successful commercialization.
• Bacteria may develop resistance to ORLYNVAH or sulopenem, which could affect their revenue potential.
• Reliance on third parties, including ACS Dobfar S.p.A., for manufacturing preclinical, clinical, and commercial supplies increases the risk of insufficient quantities or unacceptable costs.
• Heavy reliance on the exclusive license agreement with Pfizer Inc.; failure to comply with obligations could lead to loss of rights important to the business.
• Inability to obtain and maintain patent protection or other intellectual property rights for ORLYNVAH or other technology and product candidates, or insufficient scope of protection, could hinder successful commercialization or effective competition.
• The price of ordinary shares has been volatile and could be subject to volatility related or unrelated to operations, potentially causing a decline in shareholder investment value.
• The volatility of shares and shareholder base (large number of retail investors) may hinder or prevent beneficial corporate initiatives due to difficulties in obtaining shareholder approval.
• Financial statements include substantial non-operating gains or losses resulting from required quarterly revaluation of outstanding derivative instruments.
• May expend limited resources to pursue a particular product candidate or indication and fail to capitalize on more profitable opportunities.
• Broad discretion in the use of funds; may not use them effectively.
• Cash and cash equivalents held in deposit accounts could be adversely affected if financial institutions holding such funds fail.
• Disruptions in the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key personnel, or otherwise prevent timely development or commercialization.
• Inability to obtain marketing approval in jurisdictions outside the United States would prevent marketing any product or product candidates outside the U.S.
• Subject to ongoing obligations and continuing regulatory review after marketing approval, which may result in significant additional expense, restrictions, or withdrawal from the market.
• Failure to comply with FDA regulations restricting the promotion of products for unapproved uses could result in criminal penalties, substantial fines, or other sanctions.
• Relationships with customers, healthcare providers, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, potentially exposing the company to penalties.
• Healthcare legislative reform measures, such as the Inflation Reduction Act of 2022, may have a material adverse effect on the business and results of operations by impacting pricing and reimbursement.
• Reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental drug pricing programs are complex and may involve subjective decisions; any failure to comply could subject the company to penalties and sanctions.
• Subject to anti-corruption laws, export control laws, customs laws, sanctions laws, and other laws governing operations; failure to comply could result in civil or criminal penalties.
• Subject to various laws protecting the confidentiality of certain patient health information; failure to comply could result in penalties and reputational damage.
• Employees, independent contractors, principal investigators, CROs, consultants, or vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards.
• Future success depends on the ability to retain the Chief Executive Officer and other key executives and to attract, retain, and motivate qualified personnel.
• May encounter difficulties in managing growth, which could disrupt operations.
• If approvals are obtained outside of the United States, the company will be subject to additional risks in conducting business in those markets.
• May engage in acquisitions that could disrupt the business, cause dilution to shareholders, or reduce financial resources.
• Has been a passive foreign investment company (PFIC) for U.S. federal income tax purposes in the past and could be in the future, which could subject U.S. Holders to adverse U.S. federal income tax consequences.
• A future transfer of ordinary shares, other than one effected by means of the transfer of book entry interests in DTC, may be subject to Irish stamp duty.
• Dividends paid by the company may be subject to Irish dividend withholding tax.
• Ordinary shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.
• An active trading market for ordinary shares may not be sustained.
• The issuance of additional ordinary shares may dilute existing shareholders' level of ownership or require the company to relinquish rights.
• Sales of a substantial number of ordinary shares in the public market, or the perception that these sales could occur, could cause the share price to fall.
• Irish law differs from the laws in effect in the United States and may afford less protection to holders of securities.
• Incurred and will continue to incur increased costs as a result of operating as a public company, and management is required to devote substantial time and attention to public reporting obligations.
• Is a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make ordinary shares less attractive to investors.
• Failure to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements or comply with applicable regulations.
• Has never paid cash dividends, does not anticipate paying any cash dividends, and the ability to pay dividends, or repurchase or redeem ordinary shares, is limited by law.
• Anti-takeover provisions in the Articles of Association and under Irish law could make an acquisition more difficult, limit attempts by shareholders to replace or remove current directors and management team, and limit the market price of ordinary shares.
• Provisions in the Royalty-Linked Note (RLN) Indenture may deter or prevent a business combination that may be favorable to the holders of ordinary shares.
• Could be subject to securities class action litigation that could divert management's attention and harm the business.

Future Outlook

The company expects to launch ORLYNVAH in the U.S. by the end of August 2025 with its commercialization partner, EVERSANA. It anticipates incurring significant expenses and increased operating losses as it prepares for commercialization, seeks marketing approval for other product candidates, and pursues the development of its sulopenem program in additional indications. The company will require additional capital to fund its operations and support the commercial launch and ongoing development, and is continuously evaluating corporate, strategic, financial, and financing alternatives.

Management Comments

• "We are dedicated to maximizing the commercial potential of ORLYNVAH, the first oral branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally."
• "While we continue to engage in business development discussions with other companies regarding the potential sale, licensing, or disposal by other means of our rights to sulopenem, we are focusing the majority of our efforts and resources in preparing for the commercial launch of ORLYNVAH in the U.S. with our commercialization partner, EVERSANA Life Science Services, LLC (EVERSANA), which we expect to occur by the end of August 2025."
• "We expect to continue to incur significant expenses and increased operating losses as we prepare for the commercialization of ORLYNVAH in the U.S., seek marketing approval for other product candidates, if clinical trials are successful, and engage and pursue the development of our sulopenem program in additional indications, including through preclinical and clinical development."
• "Based on our available cash resources we do not believe that our existing cash and cash equivalents... will enable us to fund our operating expenses for the next 12 months from the date of filing this Quarterly Report on Form 10-Q. This condition raises substantial doubt about our ability to continue as a going concern."
• "We are continuously evaluating our corporate, strategic, financial and financing alternatives, with the goal of maximizing value for our stakeholders."

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industries, specifically targeting multi-drug resistant bacterial infections. It positions ORLYNVAH as a potential new treatment alternative to address growing concerns related to antibacterial resistance, particularly against certain designated microorganisms, without the known toxicities of some widely used antibiotics like fluoroquinolones. The industry faces challenges from existing well-established therapies, generic products, and the potential for bacteria to develop resistance. The regulatory landscape is also evolving with new legislation (e.g., Inflation Reduction Act) and trade policies (e.g., tariffs, Section 232 investigation on pharmaceutical imports) that could impact drug pricing, reimbursement, and supply chains.

Comparison to Industry Standards

• The company operates in a highly competitive market with numerous major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and government agencies, developing and marketing products for multi-drug resistant infections.
• Existing oral therapies for multi-drug resistant infections include levofloxacin, ciprofloxacin, nitrofurantoin, fosfomycin, amoxicillin-clavulanate, cephalexin, trimethoprim-sulfamethoxazole, pivmecillinam, and gepotidacin.
• Several IV-administered products for gram-negative infections resistant to first-line therapy are on the market, including Avycaz (AbbVie Inc. and Pfizer), Vabomere (Melinta Therapeutics, Inc.), Zerbaxa (Merck & Co.), Zemdri (Cipla Limited), Xerava (Innovia, Inc.), Recarbrio (Merck & Co), and Fetroja (Shionogi & Co., Ltd.).
• Many competitors possess significantly greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing compared to the company.
• Specific comparable financial results or project outcomes from these industry players are not provided in the filing to allow for a direct quantitative assessment against industry standards.

Legal Proceedings

• Not currently a party to any material legal proceedings and not aware of any pending or threatened litigation that could have a material adverse effect on the business, operating results, or financial condition.

Stakeholder Impact

• Shareholders face significant risk of dilution from future equity capital raises and potential loss of investment due to the company's going concern warning and accumulated losses.
• Employees may experience workforce adjustments depending on the company's ability to secure funding and execute its commercialization strategy.
• Customers (patients and healthcare providers) may gain a new oral antibacterial treatment option for uncomplicated urinary tract infections with ORLYNVAH, but its market acceptance and availability are subject to successful commercialization.
• Creditors, including Pfizer (holder of the promissory note) and Royalty-Linked Note holders, have payment obligations that are dependent on the company's future financial performance and commercial success of ORLYNVAH.
• Suppliers and partners, such as EVERSANA and ACS Dobfar, are engaged in new agreements for commercialization and manufacturing, indicating ongoing business relationships.

Next Steps

• Commercial launch of ORLYNVAH in the U.S. by the end of August 2025 with commercialization partner EVERSANA.
• Continue business development discussions with other companies regarding the potential sale, licensing, or disposition of sulopenem rights.
• Further clinical development of IV sulopenem and oral sulopenem in additional indications.
• Establish additional sources for the manufacture of oral sulopenem tablets and IV vials.
• Potentially in-license or acquire additional product candidates or technologies.
• Hire additional personnel across core commercial areas such as marketing, patient access and reimbursement, analytics and operations, and product distribution.
• Continuously evaluate corporate, strategic, financial, and financing alternatives to maximize stakeholder value.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, with current cash reserves insufficient to fund operations for the next 12 months. Efforts to sell or license key assets have failed to yield an acceptable transaction, forcing the company to self-commercialize ORLYNVAH, a costly endeavor for a company with limited operating history in commercialization. While ORLYNVAH has FDA approval, the significant financial risks, including ongoing net losses, accumulated deficit, and the need for substantial future capital raises that will likely dilute existing shareholders, suggest a high probability of further share price decline and potential loss of investment.

Keywords

Iterum Therapeutics, ORLYNVAH, sulopenem, uncomplicated urinary tract infections, uUTI, antibiotics, pharmaceutical, biotech, FDA approval, commercialization, going concern, drug development, clinical trials, financial results, SEC filing, 10-Q, healthcare, anti-infective